Evidence map›Paper›PMID 22876308›Full record

ArticlePloS one2012

Nras overexpression results in granulocytosis, T-cell expansion and early lethality in mice.

Louise Berkhoudt Lassen, Borja Ballarín-González, Alexander Schmitz, Annette Füchtbauer, Finn Skou Pedersen, Ernst-Martin Füchtbauer

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Melanoma management · 2016
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Louise Berkhoudt LassenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Borja Ballarín-González
Alexander Schmitz
Annette Füchtbauer
Finn Skou Pedersen
Ernst-Martin Füchtbauer
Aarhus University · DKAarhus University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NRAS is a proto-oncogene involved in numerous myeloid malignancies. Here, we report on a mouse line bearing a single retroviral long terminal repeat inserted into Nras. This genetic modification resulted in an increased level of wild type Nras mRNA giving the possibility of studying the function and activation of wild type NRAS. Flow cytometry was used to show a variable but significant increase of immature myeloid cells in spleen and thymus, and of T-cells in the spleen. At an age of one week, homozygous mice began to retard compared to their wild type and heterozygous littermates. Two weeks after birth, animals started to progressively lose weight and die before weaning. Heterozygous mice showed a moderate increase of T-cells and granulocytes but survived to adulthood and were fertile. In homozygous and heterozygous mice Gfi1 and Gcsf mRNA levels were upregulated, possibly explaining the increment in immature myeloid cells detected in these mice. The short latency period indicates that Nras overexpression alone is sufficient to cause dose-dependent granulocytosis and T-cell expansion.

Indexed as

Genes, LethalAnimalsDNA-Binding ProteinsGene ExpressionGene Expression RegulationGranulocyte Colony-Stimulating FactorGranulocytesGuanine Nucleotide Exchange FactorsHomozygoteLeukocytosisMiceMice, TransgenicMyeloid CellsPhenotypeProto-Oncogene Proteins p21(ras)ras Guanine Nucleotide Exchange FactorsDNA-Binding ProteinsGfi1 protein, mouseGranulocyte Colony-Stimulating FactorGuanine Nucleotide Exchange FactorsProto-Oncogene Proteins p21(ras)Rasgrp1 protein, mouseras Guanine Nucleotide Exchange FactorsSOS1 ProteinTranscription Factors

Identifiers

PMID22876308
PMCPMC3410918
OpenAlexW2119728775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.